ORTEXORTEX News
Tracking MTZ? Get live short interest, options flow, and signals on ORTEX.Sign up free →
MT
Earnings PreviewMTZ

MasTec Reports Today With Shorts Trimmed, Analysts Still Skeptical

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 30 Oct 2026, 04:01

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

MasTec reports Q3 results this morning with short sellers having steadily reduced their exposure over the past month, even as analysts keep marking down their targets ahead of the release.

Short interest has fallen from above 5.6 million shares in late September to roughly 4.49 million, bringing it to 5.8% of the free float. That is down 13.5% over the past month. The borrow market shows no stress whatsoever. Availability is running at 2,136%, meaning there are more than 21 shares available to lend for every one already borrowed. Cost to borrow is 0.39%, low in absolute terms and down 10% on the week. The setup in the lending market is entirely relaxed.

Options positioning tells a mildly more cautious story. The put/call ratio is at 0.72, above its 20-day average of 0.67 and roughly half a standard deviation elevated. That is a long way from the near-4-standard-deviation spike seen on October 19, reported in earlier ORTEX coverage. The defensiveness has faded considerably since then, even as the stock closed at $177.82 on October 29, down 1.8% on the day. For the week it is up 3.7%. Peers MYRG, PWR, and AGX all gained between 1% and 5% over the same period, so MTZ is roughly in step with the group this week, though still down 13% over the past month.

The analyst picture remains one of broad bullishness paired with persistent target compression. Since early October, seven firms have trimmed their price targets, with Citigroup cutting to $308 from $408 on October 23 and JP Morgan lowering to $303 from $369 on October 19, both while holding positive ratings. The consensus mean target of $360 sits roughly double the current share price. That gap is large enough to warrant caution: it reflects either genuine conviction that the stock has been oversold, or targets that have not fully caught up with the downward revision cycle. The bull case rests on a $21 billion backlog, book-to-bill above 1.2x, and the Superior acquisition deepening the company's power delivery and data-center exposure. The bear case centers on guidance that has been coming in below consensus: Communications revenue was cut sharply to around $3.25 billion, Q4 EBITDA was guided roughly 5% below the Street, and estimates for 2027 and beyond have been trimmed 7% to 10%.

Ownership context adds one notable layer. The Mas family, with Jorge Mas holding 14.8% and Jose Ramon Mas at 7.7% on Schedule 13D filings as last disclosed in August, are the company's dominant shareholders. Both filings carry the standard caveat that stakes are as-disclosed around the 5% threshold, and positions can change without a further filing. BlackRock built its stake materially, adding around 584,000 shares as of September 30 to reach 9.6% of shares. JP Morgan Asset Management more than doubled its position over the same period. That institutional accumulation into a falling stock is the one ownership signal that runs against the grain of the analyst target cuts.

The print will test whether the backlog and acquisition thesis can produce near-term earnings that close the gap between where targets sit and where the stock is trading.

Stocks in this article

See the live data behind this article on ORTEX.

Open MTZ on ORTEX →

How this article was generated

Generated
30 Oct 2026, 04:08
Data as of
30 Oct 2026, 04:01
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.